全文获取类型
收费全文 | 32362篇 |
免费 | 2160篇 |
国内免费 | 100篇 |
专业分类
耳鼻咽喉 | 493篇 |
儿科学 | 785篇 |
妇产科学 | 367篇 |
基础医学 | 4081篇 |
口腔科学 | 474篇 |
临床医学 | 3259篇 |
内科学 | 7459篇 |
皮肤病学 | 217篇 |
神经病学 | 3277篇 |
特种医学 | 1357篇 |
外科学 | 5372篇 |
综合类 | 300篇 |
一般理论 | 72篇 |
预防医学 | 2328篇 |
眼科学 | 421篇 |
药学 | 2003篇 |
中国医学 | 25篇 |
肿瘤学 | 2332篇 |
出版年
2023年 | 163篇 |
2022年 | 286篇 |
2021年 | 733篇 |
2020年 | 410篇 |
2019年 | 721篇 |
2018年 | 864篇 |
2017年 | 598篇 |
2016年 | 682篇 |
2015年 | 786篇 |
2014年 | 1139篇 |
2013年 | 1439篇 |
2012年 | 2355篇 |
2011年 | 2409篇 |
2010年 | 1389篇 |
2009年 | 1135篇 |
2008年 | 2166篇 |
2007年 | 2253篇 |
2006年 | 2166篇 |
2005年 | 2170篇 |
2004年 | 1934篇 |
2003年 | 1854篇 |
2002年 | 1791篇 |
2001年 | 313篇 |
2000年 | 250篇 |
1999年 | 314篇 |
1998年 | 359篇 |
1997年 | 294篇 |
1996年 | 248篇 |
1995年 | 247篇 |
1994年 | 205篇 |
1993年 | 185篇 |
1992年 | 206篇 |
1991年 | 208篇 |
1990年 | 183篇 |
1989年 | 159篇 |
1988年 | 148篇 |
1987年 | 134篇 |
1986年 | 125篇 |
1985年 | 135篇 |
1984年 | 169篇 |
1983年 | 132篇 |
1982年 | 145篇 |
1981年 | 130篇 |
1980年 | 98篇 |
1979年 | 77篇 |
1978年 | 75篇 |
1977年 | 61篇 |
1976年 | 48篇 |
1974年 | 50篇 |
1972年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
2.
3.
Andrea Stracciolini Jennifer Luz Gregory Walker Nicholas M. Edwards Avery D. Faigenbaum Gregory D. Myer 《The Physician and sportsmedicine》2020,48(2):199-207
ABSTRACT
Objective
To investigate primary care physician clinical practice patterns, barriers, and education surrounding pediatric physical activity (PA), and to compare practice patterns by discipline. 相似文献4.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
5.
6.
Gregory S. Orgel Robert A. Weston Christopher Ziebell Lawrence H. Brown 《The American journal of emergency medicine》2019,37(9):1729-1733
ObjectiveTo evaluate changes in insurance status among emergency department (ED) patients presenting in the two years immediately before and after full implementation of the Affordable Care Act (ACA).MethodsWe evaluated National Hospital Ambulatory Medical Care Survey (NHAMCS) Emergency Department public use data for 2012–2015, categorizing patients as having any insurance (private; Medicare; Medicaid; workers' compensation) or no insurance. We compared the pre- and post-ACA frequency of insurance coverage—overall and within the older (≥65), working-age (18–64) and pediatric (<18) subpopulations—using unadjusted odds ratios with 95% confidence intervals. We also conducted a difference-in-differences analysis comparing the change in insurance coverage among working-age patients with that observed for older Medicare-eligible patients, while controlling for sex, race and underlying temporal trends.ResultsOverall, the proportion of ED patients with any insurance did not significantly change from 2012 to 2013 to 2014–2015 (74.2% vs 77.7%) but the proportion of working-age adult patients with at least one form of insurance increased significantly, from 66.0% to 71.8% (OR 1.31, CI: 1.13–1.52). The difference-in-differences analysis confirmed the change in insurance coverage among working-age adults was greater than that seen in the reference population of Medicare-eligible adults (AOR 1.70, CI: 1.29–2.23). The increase was almost entirely attributable to increased Medicaid coverage.ConclusionIn the first two years following full implementation of the ACA, there was a significant increase in the proportion of working-age adult ED patients who had at least one form of health insurance. The increase appeared primarily associated with expansion of Medicaid. 相似文献
7.
Ramya C. Mosarla Muthiah Vaduganathan Arman Qamar Javid Moslehi Gregory Piazza Robert P. Giugliano 《Journal of the American College of Cardiology》2019,73(11):1336-1349
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer. 相似文献
8.
9.
Implications for Practice
Breast cancer is far more curable than in the past but requires multimodality treatment. Great care must be taken to use the least leukemogenic treatment programs that do not sacrifice efficacy. Elimination of radiation and anthracycline/alkylating agent regimens will be helpful where possible, particularly in younger patients and possibly those with homologous repair deficiency (HRD). Use of colony-stimulating factors should be limited to those who truly require them for safe chemotherapy administration. Further study of a possible leukemogenic association with HRD and the various forms of colony-stimulating factors is badly needed.10.